Androgen Receptor and Tumor‐Associated Neutrophil Expression Across Breast Cancer Subtypes: Associations With Clinicopathological Characteristics
Open Access
- 1 January 2025
- journal article
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2025 (1) , 8209394
Abstract
Objectives: This study is aimed at evaluating androgen receptor (AR) and tumor‐associated neutrophil (TAN) expressions in different breast cancer subtypes and their relationship with tumor differentiation, stage, and other clinicopathological markers. Methods: A cross‐sectional study was conducted on 84 breast cancer patients at Stages I–IV. Tumor tissues were assessed using immunohistochemistry for ER, PR, HER2, AR, and Ki67, along with TAN evaluation using hematoxylin and eosin staining. Associations between AR, TAN, and other clinical variables were analyzed using chi‐square, t ‐tests, and logistic regression. Results: AR was expressed in 70.2% of tumors and was significantly associated with ER positivity (OR = 74.31, p < 0.001), PR positivity (OR = 6.8, p = 0.01), and better differentiation (OR = 0.1 for poorly differentiated tumors, p = 0.035). AR positivity was highest in Luminal A/B subtypes (82%) and lowest in triple‐negative breast cancer (TNBC) (20%; OR = 0.06, 95% CI: 0.01–0.3). In contrast, TAN positivity was observed in 45.6% of cases and was most frequent in TNBC (67%; OR = 3.7, 95% CI: 0.9–15.3) and poorly differentiated tumors (71.4%). TANs were inversely associated with PR positivity (OR = 0.21, p = 0.014) and showed a significant association with vascular invasion ( p = 0.047). No significant associations were found between AR or TAN expression and metastatic status or neural invasion. Conclusion: AR is a defining marker for HR‐positive breast cancers and may serve as an indicator of lower tumor grade and differentiation status. TANs, however, are linked to more aggressive phenotypes, especially in TNBC, suggesting a role in driving tumor progression. This highlights the potential for AR and TAN expression patterns to refine patient stratification across breast cancer subtypes.Keywords
This publication has 36 references indexed in Scilit:
- A key regulator of tumor-associated neutrophils: the CXCR2 chemokine receptorJournal of Molecular Histology, 2024
- Negative estrogen receptors and positive progesterone receptors breast cancersJournal of Gynecology Obstetrics and Human Reproduction, 2021
- CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune CytotoxicityImmunity, 2020
- Molecular Subtypes and Prognosis in Young Mexican Women With Breast CancerClinical Breast Cancer, 2017
- Targeting the Androgen Receptor in Breast CancerCurrent Oncology Reports, 2015
- Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypesBreast Cancer Research and Treatment, 2014
- Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcomeBreast Cancer Research and Treatment, 2013
- Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancersBreast Cancer Research and Treatment, 2010
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiationLaboratory Investigation, 2010
- Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breastHuman Pathology, 2008